Shoichi Ozawa

Shoichi Ozawa currently serves as a Manager at SBI Investment since June 2023 and holds multiple positions as a Board observer at various companies, including Veneno Technologies Co. Ltd., 株式会社レボルカ, MiraBiologics Inc., and アリヴェクシス株式会社 since June 2024, as well as Molcure and TAGCYX BIOTECHNOLOGIES INC. since August 2023. Additionally, Shoichi Ozawa is an Investor at IgGenix, Inc. since January 2024. Previously, from February 2021 to May 2023, Shoichi Ozawa was the Clinical Science Lead at Oncolys BioPharma Inc., and worked as a Scientific Alliance Manager at InfiniteBio from February 2020 to November 2020. Shoichi Ozawa earned a Bachelor of Pharmacy (BPharm) from Kyoto Pharmaceutical University in 2016 and obtained a certification in Biotechnology from UCSC Silicon Valley Extension in 2019, alongside language learning at EC English Language Centres and EC English Language Center at UCSC Silicon Valley Extension in 2018.